BioArctic AB banner

Intrinsic Value

The intrinsic value of BioArctic AB (BRCTF) under the Base Case is 19.2 USD per share. Compared with the current market price of 30.1 USD, the stock appears Overvalued by 36% .

The intrinsic value is the average of valuations using the DCF method and multiples.

Do our valuations actually work? See backtest results .

BRCTF Intrinsic Value
$19.2
Overvaluation 36%
Intrinsic Value
Price $30.1
Alert me when BRCTF is below its intrinsic value
Today $15.36 · 49.0% below the current price

BRCTF is valued in line with its history. A premium of this size has been typical over the past 4 years.

Alternatives to BRCTF

Fundamental Analysis

What BioArctic AB Does

Biotechnology Health Care

BioArctic is a Swedish drug company focused on treatments for neurodegenerative diseases, especially Alzheimer’s disease and Parkinson’s disease. It does not run a broad consumer business; instead, it discovers and develops medicines and then partners with larger pharmaceutical companies to test, manufacture, and sell them. Its best-known work is around antibody-based drugs that target harmful proteins in the brain.

Headquarters
Sweden SE
Employees
49
IPO date
Oct 12, 2017
Read the full company overview
View Company Overview
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Past 12 months

Continue BRCTF Research

Decided on BioArctic? Get an email when BRCTF reaches the price you’d buy at. Free with an account.

Other BioArctic listings

What is the Intrinsic Value of one BRCTF stock?

The intrinsic value for BioArctic AB (BRCTF) under the Base Case is 19.2 USD.

Is BRCTF stock undervalued or overvalued?

Compared with the current market price of 30.1 USD, the stock appears Overvalued by 36% .

How reliable are our estimates? See how past valuations played out
Back to Top